// App-Quantinova.ai

: Estimated lifetime effectiveness of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler (BGF MDI) versus dual LAMA/LABA and ICS/LABA therapies in moderate-to-very severe COPD

Researchers

Presenter

  • Maria Polyzoi

Principal Investigators

  • Catrin Treharne

  • Charles Mccrea

  • Sophie Arnetorp

  • Enrico de Nigris

  • Ulf Holmgren

  • Paul Miller

  • Precil Varghese

  • John Haughney

Medical Centers

  • PAREXEL International, Stockholm, Sweden

  • 2PAREXEL International, London, UK London United Kingdom

  • AstraZeneca, Gothenburg, Mölndal, Sweden.

  • Miller Economics Ltd, Manchester, United Kingdom

  • AstraZeneca Gaithersburg, Gaithersburg, United States of America

  • Clinical R&D, NHS Greater Glasgow & Clyde, Queen Elizabeth University Hospital, Glasgow, United Kingdom

Locations

  • Sweden

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

Disease

  • Chronic obstructive pulmonary disease

Biomarkers

  • N/A

Drug/Treatment

  • Formoterol/glycopyrrolate

  • Budesonide

  • Formoterol

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT02497001

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved